News & Blog

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

January 2024 – Advocacy Newsletter

Meet the Community 2: A Closer Look – Kate Walker

Meet the Community – Sam Blade

Meet the Community – Tihana Prelevic

Meet the Community 2: A Closer Look – Esteban Luis Grieb

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Meet the Community – Fabian B

Meet the Community – Marguerite Black

Meet the Community – Katie Snead

Meet the Community 2: A Closer Look – Don Royer